Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current Assets
Cash and cash equivalents	$ 24,483	$ 24,165
Accounts receivable, net	253	621
Inventories	11,273	7,883
Interest receivable	19	12
Other current assets	8,245	5,335
Total Current Assets	44,273	38,016
Restricted cash	6,386	10,425
Accounts receivable, net of current portion		266
Property and equipment, net	7,197	5,772
Goodwill	71,038	68,697
Other long term assets	279	63
Total Assets	183,724	176,249
Current Liabilities
Accounts payable	2,625	3,984
Accrued expenses	8,926	8,206
Contingent consideration – current portion	6,958	10,502
Notes payable - current portion, net of debt discount		7,997
Total Current Liabilities	18,509	30,689
Long Term Liabilities
Contingent consideration – less current portion	11,446	12,298
Notes payable - less current portion, net of debt discount	12,825	4,995
Warrant liabilities	31,156
Net deferred tax liabilities	9,223	10,397
Total Liabilities	83,159	58,379
Commitments and Contingencies
Stockholders’ Equity
Common stock $0.001 par value, 750,000,000 shares authorized at September 30, 2017, and December 31, 2016; 155,283,207 and 115,781,030 shares issued at September 30, 2017 and December 31, 2016, respectively; and 155,281,071 and 115,687,351 shares outstanding at September 30, 2017 and December 31, 2016, respectively	155	115
Additional paid-in capital	468,150	426,609
Accumulated deficit	(371,484)	(302,844)
Treasury stock at cost, 2,136 and 93,679 shares at September 30, 2017 and December 31, 2016, respectively	(2)	(241)
Accumulated other comprehensive income (loss)	3,746	(5,769)
Total Stockholders’ Equity	100,565	117,870
Total Liabilities and Stockholders’ Equity	183,724	176,249
Intellectual Property, Net [Member]
Current Assets
Intangible assets	36,663	37,090
In-Process Research and Development [Member]
Current Assets
Intangible assets	$ 17,888	$ 15,920